theMednetRegister

COVID-19

Benign Hematology   

Questions discussed in this category

Is rituximab for refractory ITP contraindicated in the setting of an active COVID infection, particularly in a patient with asymptomatic COVID?
2 Answers available
In a patient with a bleeding disorder, how would one approach anticoagulation during active COVID infection?
Bleeding disorder such as vWD
1 Answer available
How have you been counseling patients with sickle cell regarding a 3rd COVID vaccine?
3 Answers available
Should we recommend the COVID-19 booster vaccine to patients who had a DVT or any other complications such as hemolytic anemia or thrombocytopenia from prior vaccine doses?
2 Answers available
In a patient with a heterozygous prothrombin gene mutation who has COVID with minimal symptoms, do you recommend prophylactic and/or therapeutic anticoagulation?
1 Answer available
Do you routinely check platelet counts after COVID-19 vaccines in patients with chronic ITP?
1 Answer available
Do you recommend COVID vaccination in patients with antiphospholipid antibody positivity or other prothrombotic states not on anti-coagulation?
1 Answer available
What hematologic conditions are contraindications for a COVID vaccine?
2 Answers available
In which patients with oncologic or hematologic disorders are you recommending a 3rd dose of mRNA COVID vaccine?
2 Answers available
How do you advise a patient with VTE on indefinite anticoagulants regarding the Ad26.COV2.S Johnson & Johnson/Janssen COVID vaccine?
1 Answer available
How would you advise patients with known stable autoimmune thrombocytopenia regarding the Ad26.COV2.S (Johnson & Johnson/Janssen) vaccine?
1 Answer available
In patients with a history of HIT, how do you counsel them on the use of the AstraZeneca vaccine given reports of unusual thrombosis and association with PF4/heparin antibodies?
AstraZeneca may cause PF4 antibodies leading to vaccine-induced prothrombotic immune thrombocytopenia (VIPIT). 
1 Answer available
What are the current official guidelines regarding COVID-19 vaccination for patients with cancer or for hematologic conditions?
2 Answers available
What is the optimal VTE prophylaxis for hospitalized patients with COVID-19?
Should we use a different dose in critically ill patients in the ICU? When should we consider intermediate-dose anticoagulation?
1 Answer available


Papers discussed in this category

Blood,
Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance.
N Engl J Med, 2021 Apr 14
Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination.
Ann Oncol, 2021 Mar 18
Association of Clinical Factors and Recent Anti-Cancer Therapy with COVID-19 Severity among Patients with Cancer: A Report from the COVID-19 and Cancer Consortium.
Semin Hematol,
Epidemiology and risk factors for venous thrombosis.
Am J Hematol, 2021 Jun 29
BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies.
Blood, 2010-11-04
Severe pandemic H1N1 and seasonal influenza in children and young adults with sickle cell disease.
Pediatric blood & cancer, 2014-05
Respiratory syncytial virus and seasonal influenza cause similar illnesses in children with sickle cell disease.
British journal of haematology, 2015-05
Immune parameter analysis of children with sickle cell disease on hydroxycarbamide or chronic transfusion therapy.
Oman Med J, 2020 Nov 07
Respiratory Viral Infections in Sickle Cell Anemia: Special Emphasis on H1N1 Co-infection.
Pediatr Blood Cancer, 2020 Sep 08
Fatal viral infections in hemoglobin sickle cell C patients.
Blood Adv,
COVID-19 in individuals with sickle cell disease/trait compared with other Black individuals.
Hemoglobin, 2021 May 24
Incidence Rate of COVID-19 Infection in Hemoglobinopathies: A Systematic Review and Meta-analysis.
Thromb Res, 2021 Jun 25
Absence of hypercoagulability after nCoV-19 vaccination: An observational pilot study.

Related Topics in COVID-19

Copyright © 2025 theMednet
All Rights Reserved.